Nautilus Biotechnology (NAUT) - Pangali Forward P/E
Nautilus Biotechnology (NAUT) faces challenges in the commercialization of proteomics and a shortage of funds prior to reaching break-even. The company's expected P/E ratio on the GURU.Markets system summary chart reflects market expectations, where 0.00 determines this parameter level. Equipment delivery requires precision electronics packaging, while the business's future pricing power depends on the technology's efficiency compared to mass spectrometry.
Rincian analitis lan laporan data perusahaan Nautilus Biotechnology Inc (NAUT)
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi pasar:
- informasi kapitalisasi buku:
- rincian utang lan likuiditas:
Utang marang Ekuitas Nautilus Biotechnology|NAUT - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Nautilus Biotechnology|NAUT - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Nautilus Biotechnology, Inc.|NAUT - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Nautilus Biotechnology|Likuiditas cepet nautilus.bio
- indikator profitabilitas perusahaan lan kelipatan valuasi:
NAUT - Penghasilan resik perusahaan|Bathi mangsa ngarep Nautilus Biotechnology|NAUT - Rasio rega pasar marang bathi resik|Pangali Forward P/E Nautilus Biotechnology|NAUT - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Nautilus Biotechnology, Inc.|NAUT - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Nautilus Biotechnology|NAUT - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan nautilus.bio|NAUT - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Nautilus Biotechnology
Pambiji fundamental:Nautilus Bio
Cost optimization at Nautilus Biotechnology (NAUT) through the outsourcing of materials production and cloud-based data analysis directly impacts the business's future margins. By analyzing the company's forward P/E ratio, an investor can see the relationship between current market value and expected earnings, allowing for an objective assessment of the asset's overbought status and the avoidance of excessive risks when constructing a portfolio.
Perusahaan pesaing
Prakiraan rega marang bathi TEM (Tempus Labs)|Rasio kapitalisasi marang bathi mangsa ngarep QGEN|Pangali Forward P/E IONS (Ionis Pharma)|Kapitalisasi marang proyeksi bathi Repligen Inc. (RGEN)|RNA - Rega marang bathi mangsa ngarep|CRSP: Rega marang bathi mangsa ngarep|WGS (GeneDx) - Prakiraan rega marang bathi|Ultragenyx Pharmaceutical Inc. (RARE) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Beam Therapeutics Corp|Sarepta Corp (SRPT) - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi TWST (Twist Bioscience)|TXG (10xgenomics.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E NTLA (Intellia Therapeutics, Inc.)|Stoke Therapeutics Inc - Rega marang bathi mangsa ngarep|BioLife Corp - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi Wave Pharma WVE|Maze Therapeutics Inc (MAZE) - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi sionnatx.com (SION)|Prakiraan rega marang bathi PRME|TSHA (Taysha Gene Therapies Inc) - Rasio kapitalisasi marang bathi mangsa ngarep|Pangali Forward P/E QURE|MGTX - Rasio prakiraan rega marang bathi|Pangali Forward P/E RGNX (REGENXBIO Inc.)|SLDB - Prakiraan rega marang bathi|Ocugen - Pangali Forward P/E|Pangali mangsa ngarep rega marang bathi PACB (Pacific Biosciences of California, Inc.)|Benitec (BNTC) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep DSGN|Rega marang bathi mangsa ngarep Rocket Pharmaceuticals|Rasio prakiraan rega marang bathi 4dmoleculartherapeutics.com FDMT|Rega marang bathi mangsa ngarep Lexeo Therapeutics (LXEO)|Rega marang bathi mangsa ngarep KRRO (korrobio.com)|Rega marang bathi mangsa ngarep Editas EDIT|Silence Therapeutics Corp (SLN) - Rasio prakiraan rega marang bathi|ProQR Therapeutics NV - Pangali Forward P/E|Pangali forward rega marang bathi Codexis, Inc. (CDXS)|SGMO (Sangamo Therapeutics, Inc.) - Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi Metagenomi Inc. (MGX)|Rega marang bathi mangsa ngarep Precision BioSciences, Inc.|Rasio rega marang bathi mangsa ngarep GBIO (Generation Bio Corp)|Pangali Forward P/E BOLD|Pangali Forward P/E exicuretx.com (XCUR)|Imunon - Prakiraan rega marang bathi|Pangali Forward P/E Phio Pharmaceuticals Corp PHIO|MBIO: Prakiraan rega marang bathi|TransCode Therapeutics - Rasio kapitalisasi marang bathi mangsa ngarep|BNGO: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep APDN|Rega marang bathi mangsa ngarep bluebird bio|Rasio rega marang bathi mangsa ngarep IPA (ImmunoPrecise)|Pangali Forward P/E OMGA|Pangali Forward P/E Singular Genomics Corp (OMIC)|Rega marang bathi mangsa ngarep Regulus Therapeutics RGLS|SYRS: Rasio rega marang bathi mangsa ngarep|Telesis Bio - Pangali Forward P/E|TCON - Pangali Forward P/E|UBX (Unity Bio) - Prakiraan rega marang bathi
